Advances in the Pathogenesis and Treatment Strategies for Type 1 Diabetes Mellitus.

IF 4.7 2区 医学 Q2 IMMUNOLOGY International immunopharmacology Pub Date : 2025-02-20 Epub Date: 2025-02-01 DOI:10.1016/j.intimp.2025.114185
Meiheng Du, Sihong Li, Jun Jiang, Xiang Ma, Lu Liu, Tao Wang, Jufang Zhang, Dong Niu
{"title":"Advances in the Pathogenesis and Treatment Strategies for Type 1 Diabetes Mellitus.","authors":"Meiheng Du, Sihong Li, Jun Jiang, Xiang Ma, Lu Liu, Tao Wang, Jufang Zhang, Dong Niu","doi":"10.1016/j.intimp.2025.114185","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is a complex autoimmune disorder distinguished by the infiltration of immune cells into pancreatic islets, primarily resulting in damage to pancreatic β-cells. Despite extensive research, the precise pathogenesis of T1D remains elusive, with its etiology linked to a complex interplay of genetic, immune, and environmental factors. While genetic predispositions, such as HLA and other susceptibility genes, are necessary, they do not fully account for disease development. Environmental influences such as viral infections and dietary factors may contribute to the disease by affecting the immune system and epigenetic modifications. Additionally, endogenous retroviruses (ERVs) might play a role in T1D pathogenesis. Current therapeutic approaches, including insulin replacement therapy, immune omodulatory therapy, autoantigen immunotherapy, organ transplantation, and genetic modification, offer potential to alter disease progression but are still constrained by limitations. This review presents updated knowledge on T1D, with a focus on risk factors, predisposing hypotheses, and recent advancements in therapeutic strategies.</p>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"148 ","pages":"114185"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.intimp.2025.114185","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Type 1 diabetes (T1D) is a complex autoimmune disorder distinguished by the infiltration of immune cells into pancreatic islets, primarily resulting in damage to pancreatic β-cells. Despite extensive research, the precise pathogenesis of T1D remains elusive, with its etiology linked to a complex interplay of genetic, immune, and environmental factors. While genetic predispositions, such as HLA and other susceptibility genes, are necessary, they do not fully account for disease development. Environmental influences such as viral infections and dietary factors may contribute to the disease by affecting the immune system and epigenetic modifications. Additionally, endogenous retroviruses (ERVs) might play a role in T1D pathogenesis. Current therapeutic approaches, including insulin replacement therapy, immune omodulatory therapy, autoantigen immunotherapy, organ transplantation, and genetic modification, offer potential to alter disease progression but are still constrained by limitations. This review presents updated knowledge on T1D, with a focus on risk factors, predisposing hypotheses, and recent advancements in therapeutic strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1型糖尿病的发病机制及治疗策略研究进展。
1型糖尿病(T1D)是一种复杂的自身免疫性疾病,以免疫细胞浸润胰岛为特征,主要导致胰腺β细胞损伤。尽管进行了广泛的研究,但T1D的确切发病机制仍然难以捉摸,其病因与遗传、免疫和环境因素的复杂相互作用有关。虽然遗传倾向,如HLA和其他易感基因是必要的,但它们并不能完全解释疾病的发展。病毒感染和饮食因素等环境影响可能通过影响免疫系统和表观遗传修饰而导致该病。此外,内源性逆转录病毒(ERVs)可能在T1D发病机制中发挥作用。目前的治疗方法,包括胰岛素替代疗法、免疫调节疗法、自身抗原免疫疗法、器官移植和基因改造,提供了改变疾病进展的潜力,但仍然受到局限性的制约。这篇综述介绍了关于T1D的最新知识,重点是危险因素、易感假设和治疗策略的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
3.60%
发文量
935
审稿时长
53 days
期刊介绍: International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.
期刊最新文献
Retraction notice to "Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats" [Int. Immunopharmacol. 86 (2020) 106768]. Corrigendum to "Integrated bioinformatics and machine learning deciphering IL12RB2 and FYN as key immune biomarkers in brucellosis" [Int. Immunopharmacol. 173 (2026) 116268]. 1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3. Improved survival with SBRT plus PD-1/PD-L1 inhibitors in lung metastases patients: A propensity score-matched study. Impinging flow regulates endothelial cell injury via HMGB1-mediated ferroptosis to promote intracranial aneurysm formation and progression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1